New York, 16 November 2009 - Elsevier is pleased to announce that beginning with Volume 104 (2010) it will assume publication of the Annals of Allergy, Asthma & Immunology, the official journal of the American College of Allergy, Asthma & Immunology (ACAAI).
The Annals of Allergy, Asthma & Immunology, published since 1942, will continue under the leadership of Editor Gailen D. Marshall, MD, PhD and a distinguished editorial board. The journal provides solid, peer-reviewed coverage of current clinical science (both research and practice-based) that is readily applicable to both the clinician and the researcher in the fields of allergy, asthma, and immunology. Each monthly issue also provide opportunities to participate in accredited continuing medical education activities to enhance overall clinical proficiency.
Andrew Berin, Health Sciences Publisher, commented, "Elsevier is delighted to add Annals of Allergy, Asthma & Immunology to our publishing program. Working in partnership with the Editor, Editorial Board and the American College of Allergy, Asthma & Immunology, our goal is to continue to underscore the journal's mission of providing research and clinically relevant information to the widest possible audience of practicing allergists and immunologists."
Dr. Marshall stated, "We, at Annals, are pleased to have entered into this partnership with the largest and most respected publishing house in the fields of science and medicine. Our intent is to continue to strive for excellence and relevance. Our Board and the College are excited by the possibilities."
Elsevier, a world-leading medical and scientific publisher, brings the full support of its global organization to the journal. It is recognized for its numerous long-standing and successful society-publishing partnerships, as well as excellence in all aspects of the publishing process. 
ScienceDirect, Elsevier's world-class electronic platform with over 11 million users, will provide online access to the full text of the Annals of Allergy, Asthma and Immunology (current and archived issues) to institutional subscribers. Members of the ACAAI and individual subscribers will be able to access the journal via
www.annallergy.org
# # #
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including
The Lancet and
Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include
ScienceDirect,
Scopus,
Reaxys,
MD Consult and
Nursing Consult, which enhance the productivity of science and health professionals, and the
SciVal suite and
MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam,
Elsevier employs 7,000 people worldwide. The company is part of
Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact:
Andrew Berin
Elsevier
+1 212 633 3887
a.berin@elsevier.com
